Posttransplantation lymphoproliferative disease in miniature swine after allogeneic hematopoietic cell transplantation: similarity to human PTLD and association with a porcine gammaherpesvirus
Ca. Huang et al., Posttransplantation lymphoproliferative disease in miniature swine after allogeneic hematopoietic cell transplantation: similarity to human PTLD and association with a porcine gammaherpesvirus, BLOOD, 97(5), 2001, pp. 1467-1473
Posttransplantation lymphoproliferative disease (PTLD) is a major complicat
ion of current clinical transplantation regimens. The lack of a reproducibl
e large-animal model of PTLD has limited progress in understanding the path
ogenesis of and in developing therapy for this clinically important disease
. This study found a high incidence of PTLD in miniature swine undergoing a
llogeneic hematopoietic stem cell transplantation and characterized this di
sease in swine. Two days before allogeneic peripheral blood stem cell trans
plantation, miniature swine were conditioned with thymic irradiation and in
vivo T-cell depletion. Animals received cyclosporine daily beginning 1 day
before transplantation and continuing for 30 to 60 days. Flow cytometry an
d histologic examination were performed to determine the cell type involved
in lymphoproliferation. Polymerase chain reaction was developed to detect
and determine the level of porcine gammaherpesvirus in involved lymph node
tissue. PTLD in swine is morphologically and histologically similar to that
observed in human allograft recipients. Nine of 21 animals developed a B-c
ell lymphoproliferation involving peripheral blood (9 of 9), tonsils, and l
ymph nodes (7 of 9) from 21 to 48 days after transplantation. Six of 9 anim
als died of PTLD and 3 of 9 recovered after reduction of immunosuppression.
A novel porcine gammaherpesvirus was identified in involved tissues. Minia
ture swine provide a genetically defined large-animal model of PTLD with ma
ny characteristics similar to human PTLD. The availability of this reproduc
ible large-animal model of PTLD may facilitate the development and testing
of diagnostic and therapeutic approaches for prevention or treatment of PTL
D in the clinical setting. (Blood, 2001;97:1467-1473) (C) 2001 by The Ameri
can Society of Hematology.